<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924402</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb13676-01</org_study_id>
    <nct_id>NCT02924402</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of weekly intravenous
      (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) after
      the first dose, and then to determine the MTD after second and subsequent infusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will enroll two parallel disease groups: patients with non-CLL B cell malignancies and patients with CLL/SLL/Ricter's Transformation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as determined by the number of participants with treatment-related adverse events</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
    <description>treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
    <description>Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>B-cell Non-Hodgkins Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV weekly up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLL/SLL (Group CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb13676 administered IV weekly up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb13676</intervention_name>
    <description>Biological</description>
    <arm_group_label>CLL/SLL (Group CLL)</arm_group_label>
    <arm_group_label>Non-CLL B Cell Malignancies (Group NHL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Diagnosis of either Non-CLL B cell malignancy or CLL/SLL

          -  Ineligible for or have exhausted standard therapeutic options

          -  Last dose of anti-CD20 antibody therapy must have been &gt;4 weeks before the first dose
             of XmAb13676

          -  ECOG performance status 0-2

          -  Not a candidate for or refusing treatment with hematopoietic stem cell transplantation

          -  Fertile patients must agree to use effective contraception during and for 4 weeks
             after completion of study

          -  Able and willing to complete the entire study

        Exclusion Criteria:

          -  Cytotoxic chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or small
             molecule or investigational agents within 6 elimination half-lives of the first dose
             of XmAb13676

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Failure to recover from Grade 3 or 4 toxicity from previous treatment

          -  Multiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemia

          -  Known intolerance to CD20 monoclonal antibody therapy

          -  History of primary central nervous system lymphoma or neoplastic central nervous
             system disease

          -  Platelet count &lt; 50 x 10^9/L

          -  Absolute neutrophil count &lt; 1.0 x 10^9/L

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening &gt; 3x
             upper limit of normal (ULN)

          -  Bilirubin &gt; 1.5 mg/dL

          -  Estimated creatinine clearance &lt; 50 mL/min

          -  Active/uncontrolled autoimmune disease

          -  Clinically significant cardiac/cardiovascular disease, or pulmonary compromise

          -  Seizure disorder

          -  History of stroke with the past year

          -  History or evidence of a clinically unstable/uncontrollable disorder, condition or
             disease other than primary malignancy, that in the opinion of the Investigator would
             pose a risk to the patient safety or interfere with the study evaluation, procedures
             or completion

          -  Evidence of any serious bacterial, viral, parasitic or systemic fungal infections
             within the 30 days prior to study entry

          -  Positive test for human immunodeficiency virus (HIV) or hepatitis C (HCV) antibodies
             (unless HCV viral load test by PCR is negative)

          -  Positive test for HbsAg, or positive test for HBcAb (unless serology is positive due
             to recent intravenous immunoglobulin therapy). HBcAb positivity will be allowed if
             HBsAb is present.

          -  Patient is pregnant or breast feeding, or planning to become pregnant while enrolled
             in the study, up to the End of Study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Saville, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Oncology Clinical Development, Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Liebowitz, MD</last_name>
    <phone>858-617-6160</phone>
    <phone_ext>260</phone_ext>
    <email>dliebowitz@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chelsea Johnson</last_name>
    <phone>858-480-3891</phone>
    <phone_ext>159</phone_ext>
    <email>cjohnson@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsak Vimoktayon</last_name>
      <phone>904-953-3238</phone>
      <email>vimoktayon.torsak@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lula Downey</last_name>
      <phone>904-953-3087</phone>
      <email>downey.lula@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tycel Phillips, MD</last_name>
      <phone>734-647-8901</phone>
      <email>tycelp@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center and James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Byrd, MD</last_name>
      <phone>614-293-8330</phone>
      <email>john.byrd@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Scott Corney</last_name>
      <phone>(614) 688-8949</phone>
      <email>Scott.Corney@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Wierda, MD</last_name>
      <email>wwierda@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Jeanne Lichty, RN</last_name>
      <phone>713-794-4683</phone>
      <email>jmlichty@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheeba Thomas, MD</last_name>
      <phone>713-792-2860</phone>
      <email>SThomas@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Morphey</last_name>
      <phone>713-792-8785</phone>
      <email>Alandry1@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UVA Health System, Division of Hematology &amp; Oncology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Portell, MD</last_name>
      <phone>434-982-4982</phone>
      <email>CP4YS@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krish Patel, MD</last_name>
      <phone>206-215-2338</phone>
      <email>krish.patel@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Tenzin Tsomo</last_name>
      <phone>206-386-2831</phone>
      <email>Tenzin.Tsomo@swedish.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Corinne Haioun</last_name>
      <phone>33 1 49 81 20 51</phone>
      <email>corinne.haioun@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette Dpt of Oncology/Hematology</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda Bouabdallah, MD</last_name>
      <phone>33 6 70 27 68 77</phone>
      <email>bouabdallahr@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier, Hematologie Clinique St. Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Guillaume Cartron</last_name>
      <phone>33 4 67 33 26 45</phone>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr. Frederic Peyrade</last_name>
      <phone>33 4 92 03 10 47</phone>
      <email>frederic.peyrade@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal Krimo Bouabdallah, MD</last_name>
      <phone>33 5 57 65 65 11</phone>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud, Service d'Hematologie</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr Gilles Salles</last_name>
      <phone>33 4 78 86 43 07</phone>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Herv√© Tilly</last_name>
      <phone>33 2 32 08 22 20</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Vincent Ribrag</last_name>
      <phone>33 1 42 11 58 20</phone>
      <email>mathilde.miyalou@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>B-cell Prolymphocytic Leukemia</keyword>
  <keyword>Transformed Lymphoma</keyword>
  <keyword>Burkitt's Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Hairy Cell Leukemia</keyword>
  <keyword>Splenic Marginal Zone Lymphoma</keyword>
  <keyword>Waldenstrom's Macroglobulinemia</keyword>
  <keyword>Variant Hairy Cell Leukemia</keyword>
  <keyword>Splenic B-cell Lymphoma/Leukemia</keyword>
  <keyword>Lymphoplasmacytic Lymphoma</keyword>
  <keyword>Extranodal Marginal Zone Lymphoma (MALT)</keyword>
  <keyword>MALT Lymphoma</keyword>
  <keyword>Nodal Marginal Zone Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>In Situ Follicular Neoplasia</keyword>
  <keyword>Duodenal-type Follicular Lymphoma</keyword>
  <keyword>Large B-cell Lymphoma with IRF4 rearrangement</keyword>
  <keyword>Primary Cutaneous Follicle Center Lymphoma</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>T-cell/Histiocyte-Rich Large B-cell Lymphoma</keyword>
  <keyword>Primary Cutaneous DLBCL, leg type</keyword>
  <keyword>EBV-positive DLBCL, NOS</keyword>
  <keyword>EBV-positive Mucocutaneous Ulcer</keyword>
  <keyword>DLBCL Associated with Chronic Inflammation</keyword>
  <keyword>Lymphomatoid Granulomatosis</keyword>
  <keyword>Primary Mediastinal (Thymic) Large B-cell Lymphoma</keyword>
  <keyword>Intravascular Large B-cell Lymphoma</keyword>
  <keyword>ALK+ Large B-cell Lymphoma</keyword>
  <keyword>Plasmablastic Lymphoma</keyword>
  <keyword>Primary Effusion Lymphoma</keyword>
  <keyword>HHV8+ DLBCL</keyword>
  <keyword>Burkitt-like Lymphoma with 11q Aberration</keyword>
  <keyword>High-grade B-cell Lymphoma</keyword>
  <keyword>B-cell Lymphoma, unclassifiable</keyword>
  <keyword>Post-transplant Lymphoproliferative Disorder</keyword>
  <keyword>PTLD</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>High-grade Lymphoma</keyword>
  <keyword>Richter's Transformation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

